News
GLP-1 Drugs and Neuroendocrine Cancer: What a New Study Suggests
By Anna Greene, PhD, NETRF Chief Scientific Officer Drugs like Ozempic®, Wegovy®, and Mounjaro®, known as GLP-1 receptor agonists, are now widely used to treat
Looking Ahead: Hope, Discovery, and Momentum from the 2025 NETRF Research Symposium
By Anna Greene, PhD, NETRF Chief Scientific Officer Each year, the Margie & Robert E. Petersen NETRF Research Symposium brings together leading scientists, clinicians, and
The Grewal Research Update on NANETS 2025
By Udhayvir Singh Grewal, MD, Assistant Professor of Medical Oncology, Emory University School of Medicine Guest Contributor The Annual NANETS Multi-Disciplinary Symposium 2025 was a
SPORE Grant Awarded to the University of Iowa to Study Neuroendocrine Cancer
Congratulations to Dr. Dawn Quelle, NETRF Board of Scientific Advisors co-chair, and the team at the University of Iowa Health, for winning a $10.7 million
Clinical Advances, Research Progress, and Patient Advocacy Celebrated at NANETS Annual Meeting
NETRF CEO Elyse Gellerman, Chief Scientific Officer Anna Greene, and Director of Patient Education Jessica Thomas joined hundreds of neuroendocrine cancer specialists and patient advocates
Understanding Patient Perspectives on Radioligand Therapy for GEP-NETs
A recent review published in the Journal of Oncology Practice explores how patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) view the use and timing of radioligand
Nuclear Medicine Pilot Research Grant Recognizes Innovation in NET Nuclear Medicine and Imaging
The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) in partnership with NETRF is proud to announce Dr. Carolin Kitzberger of TUM
Early Clinical Trial of 61Cu-TraceNET™ Shows Promise in Improving NET Imaging
The early results from a first-in-human clinical trial suggest that a novel copper-based PET imaging agent may deliver clearer and more comprehensive scans for people
Progress Seen in CDH17 CAR T Trial
Chimeric Therapeutics has reported that a neuroendocrine cancer patient in the Phase 1 clinical trial of CAR T cell therapy has experienced tumor shrinkage. In
New Lab Models Reveal Hidden Weaknesses in Pheochromocytoma and Paraganglioma Tumors
By Anna Greene, PhD, NETRF Chief Scientific Officer NETRF-funded scientists uncover how oxygen levels shape tumor behavior and expose new treatment opportunities for pheochromocytomas and